11 October 2023
DisCoVery publishes an article on association between SARS-CoV-2 viral kinetics and clinical score evolution in hospitalized patients
The role of antiviral treatment in COVID-19 hospitalized patients remains controversial. In this study, we analyzed nasopharyngeal viral load and the clinical score of patients (as measured by the National Early Warning Score 2 (NEWS-2)) in the DisCoVeRy trial, where 664 patients were randomized to either standard of care (SoC) or SoC + remdesivir. We used a mathematical model to model the evolution of viral dynamics and its potential impact on clinical evolution, and to model the impact of effective antiviral treatment on clinical evolution.
Simulations predicted that antiviral activity greater than 99% could reduce the time to clinical improvement by 2 days in patients with high viral loads, regardless of the NEWS2 score on admission. While no clinically substantial effect was predicted in patients with low viral loads, these results suggest that highly potent antivirals could accelerate clinical improvement in hospitalized patients with high viral loads.
This study provides new insights into the potential role of antiviral treatment in hospitalized COVID-19 patients.
Authors:
Néant N, Lingas G, Gaymard A, Belhadi D, Hites M, Staub T, Greil R, Paiva JA, Poissy J, Peiffer-Smadja N, Costagliola D, Yazdanpanah Y, Bouscambert-Duchamp M, Gagneux-Brunon A, Ader F, Mentré F, Wallet F, Burdet C, Guedj J; DisCoVeRy study group. Association between SARS-CoV-2 viral kinetics and clinical score evolution in hospitalized patients. CPT Pharmacometrics Syst Pharmacol. 2023 Sep 20. doi: 10.1002/psp4.13051. Epub ahead of print. PMID: 37728045.